or
Bookmark and Share
Method for treatment of idiopathic inflammatory bowel disease (IIBD)
   
Document Number
US Patent 5599795
Issued Date
February 4, 1997
Link
Inventors
Map
Abstract
A new method for the prevention and treatment of Idiopathic inflammatory Bowel Disease (IIBD), including Crohn's Disease and Ulcerative Colitis, in human patients is provided. The key steps include sterilizing the intestinal tract with multiple antibiotics to kill the pre-existing bacterial flora, and replacing the latter with different, select, well-characterized bacteria taken from normal humans. The new microflora serve to generate more normal metabolic and immune responses, remitting thereby the IIBD.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
3
Comments:
no comments yet
Owner
Published
February 4, 1997
Application Number
08/264,052
Filed
August 19, 1994
US Classification
424/93.4   514/192 514/198 514/200 514/28 514/31 514/398
Int'l Classification
A61K   35/66   (20060101)   A61K   35/74   (20060101)   A61K   38/14   (20060101)  
Examiner
Attorney/Law Firm
USPTO Field of Search
514/31   514/192   514/198   514/210   514/398  
Related Patents
6428783 - Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men - Owned by Medtech Center, Inc. (Glendale, CA)

The invention concerns microbiology and medicine and may be used for the prophylaxis and treatment of the syndrome of an irritated large intestine in either a human or an animal. The insertion of the samples of the strains of the autochthonous bank into the intestine of a human permits the repair of the broken bacteriocenosis of the intestine due to the use of the entire spectrum of the healthy (normal) microflora of the intestine. The method is as follows: feces samples of a single human are taken during healthy periods beginning 7-15 days after birth and continuing through the course of a lifetime no more than once a year. The autochthonous strains of the normal intestinal microflora are selected from the feces and identified; a culture of each kind of bacteria is separately made on a selective culture medium to a minimum titer of 10.sup.3 -10.sup.9 cells/ml; the biomasses of the strains are mixed and stabilized using the special stabilizer; the mixture is divided into separate samples which are conserved and stored during the entire lifetime of the human with periodic testing of the biotiter. During the storage period, a part of the bacterial samples from various periods of life are mixed in equal proportions after biotiter control-this increases the biological activity of the preparation and the acclimatization of bacteria in the human intestine. The use of the entire spectrum of the normal (healthy) autochthonous microflora of the intestine permits repair of the broken bacteriocenosis of the intestine in the process of treatment of the syndrome of irritated large intestine or to prevent the possible breach of bacteriocenosis during the treatment of the disease.

6572854 - Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria - Owned by Mendes S.r.l. (Ardea,IT)

Disclosed is the use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction, and pharmaceutical or dietetic compositions containing such bacteria. Also included is a strain of Lactobacillus brevis highly endowed with arginine deiminase.

7147847 - Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria - Owned by VSL Pharmaceuticals, Inc. (Gaithersburg, ND)

Disclosed is the use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction, and pharmaceutical or dietetic compositions containing such bacteria. Also disclosed is a strain of Lactobacillus brevis highly endowed with arginine deiminase.

7018629 - Probiotic compositions for the treatment of inflammatory bowel disease - Owned by The Bio Balance Corporation (New York, NY)

Pharmaceutical compositions of probiotic E. coli strains and uses thereof for treating inflammatory bowel disease.

6689788 - Method and composition for treatment of inflammatory bowel disease - Owned by University of Florida (Gainesville, FL)

A composition in unit dosage form for the inhibition, prevention or treatment of inflammatory bowel disease comprising an effective amount of a compound having the formula: ##STR1## and a pharmaceutically acceptable carrier therefor. Also disclosed is a method for the inhibition, prevention or treatment of inflammatory bowel disease comprising administering to a human or non-human mammal in need thereof an effective amount of a compound having the formula: ##STR2##

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us